Eribulin v lechenii metastaticheskogo raka molochnoy zhelezy s troynym negativnym fenotipom


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Patients with breast cancer (BC) without expression of estrogen, progesterone and HER-2 receptors (breast cancer with triple-negative phenotype - TNBC) have the worst prognosis, because in contrast to the hormone-positive and HER-2-positive breast cancer, we can not offer them any other treatment except chemotherapy. The problem of the choice of treatment strategy after the standard first three lines (anthracyclines, taxanes, capecitabine) is very difficult for any subtype of BC. This problem is particularly relevant for patients with TNBC, as overall survival of these patients after detection of distant metastases is still not exceed 1.5 year. Eribulin, a drug with a fundamentally new mechanism of action, has demonstrated itself as a truly effective agent for the third-line and further treatment of metastatic breast cancer improving overall survival. This article presents the results of the combined analysis of two randomized phase III trials on the effectiveness of eribulin in patients with metastatic breast cancer after anthracyclines and taxanes depending on the subtype.

Full Text

Restricted Access

References

  1. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci U S A 2001;98: 10869-874.
  2. Perou C.M. Molecular stratification of triple-negative breast cancers. Oncologist. 2011;16(Suppl 1):61-70.
  3. Baser O, Wei W., Xie L., et al. Retrospective study of patients with metastatic triple-negative breast cancer: survival, health care utilization, and cost. Commun. Oncol. 2012; 9:8-14.
  4. Prat A., Parker J.S., Karginova O., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.
  5. Foulkes W.D., Smith I.E., Reis-Filho J.S. TripleNegative Breast Cancer. N. Engl. J. Med. 2010;363:1938-48.
  6. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004;10: 5367-74.
  7. Bertucci F., Finetti P., Cervera N., et al. How basal are triple-negative breast cancers? Int. J. Cancer. 2008;123:236-40.
  8. Atchley D.P., Albarracin C.T., Lopez A., et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol. 2008;26:4282-88.
  9. Gonzalez-Angulo A.M., Timms K.M., Liu S., et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin. Cancer Res. 2011;17:1082-89.
  10. Oakman C., Viale G., Di Leo A. Management of triple negative breast cancer. Breast. 2010;19(5):312-21.
  11. Carey L., Dees E., Sawyer et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007;13(8):2329-34.
  12. Стенина М., Фролова М., Скрыпникова М. Базальноподобный (тройной негативный) рак молочной железы: молекулярные особенности, течение и возможные терапевтические подходы. Врач. 2010; 3:24-28.
  13. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 2011;5:5-23.
  14. Torrisi R., Balduzzi A., Ghisini R., et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother. Pharmacol. 2008;62:667-72.
  15. Rakha E.A., El-Sayed M.E., Green A.R., et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32.
  16. Bruce G. Haffty, Qifeng Yang, Michael Reiss et al. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer. J. Clin. Oncol. 2006;24(36):5652-57.
  17. Fan Y., Xu B.H., Yuan P., et al. Docetaxelcisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann. Oncol. 2013;24(5):1219-25.
  18. Gluz O., Nitz U.A., Harbeck N., et al. Triplenegative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: Results of WSG AM-01 trial. Ann. Oncol. 2008;19:861-70.
  19. Di Leo A., Isola J., Piette F., et al. A metaanalysis of phase III trials evaluating the predictive value of HER-2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Breast Cancer Res. Treat. 2008; 107:24.
  20. Bidard F.C., Matthieu M.C., Chollet P., et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann. Oncol. 2008;19:1261-65.
  21. Pivot X.B., Li R.K., Thomas E.S., et al. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. Eur. J. Cancer. 2009;45( 1 7):2940-46.
  22. Baselga J., Zambetti M., Llombart-Cussac A., et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol. 2009;27(4):526-34.
  23. O'Shaughnessy J., Miles D., Gray R.J. A metaanalysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J. Clin. Oncol. 2010;28(suppl 15):abstr 1005.
  24. Brufsky A., Bondarenko I., Smirnov V., et al. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. SABCS. 2009.
  25. Brufsky A., Valero V., Tiangco B., et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res. Treat. 2012;133(3):1067-75.
  26. Cardoso F., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1), Breast. 2012. doi:10.1016/j. breast.2012.03.003.
  27. Vahdat L.T., Puitt B., Fabian C.J., et al. Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. J. Clin. Oncol. 2009;27:2954-61.
  28. Cortes J., Vahdat L.T., Blum J., et al. Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine. J. Clin. Oncol. 2010; 28:3922-28.
  29. Cortes J., O'Shaughnessy J., Loesch D., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914-23.
  30. Kaufman P.A., Awada A., Twelves C., et al. A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Presented at: 2012 CTRC-AACR San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, Texas. Abstract S6-6.
  31. Kaufman P.A., Cortes J., Awada A., et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthra-cyclines and taxanes: subgroup analyses. J. Clin. Oncol. 2013;31 (suppl):abstr 1049.
  32. Twelves C., Cortes J., Vahdat L., et al. Efficacy of eribulin in patients with metastatic breast cancer: a pooled analysis by HER2 and ER status. ASCO. 2014;post.95.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies